Show simple item record

dc.contributor.authorZhang, Ruijie
dc.contributor.authorWang, Tiffany
dc.contributor.authorLin, Jiayuh
dc.date.accessioned2021-05-19T20:07:38Z
dc.date.available2021-05-19T20:07:38Z
dc.date.issued2021-05
dc.identifier.urihttp://hdl.handle.net/10713/15695
dc.description.abstractBACKGROUND/AIM: Poly (ADP-ribose) polymerase inhibitors (PARPis) are one of the targeted therapies proven to treat breast cancer gene (BRCA)-mutant ovarian cancer. Because most ovarian cancers are BRCA wild-type, it is necessary to extend the usage of PARPis. In the present study, we combined the PARPi, talazoparib, and the IL-6 inhibitor, bazedoxifene, for the treatment of human ovarian cancer cells. MATERIALS AND METHODS: The human ovarian cancer cell lines, SKOV3, UWB1.289 (BRCA1-null) and OV75, were treated with talazoparib and bazedoxifene, as monotherapy or combination treatment. The effects of treatment on cell viability, migration, growth and colony formation were examined. Western blot was used to investigate pathways that may be involved in the antitumor effects of the two agents. RESULTS: The combination of talazoparib and bazedoxifene showed synergistic inhibition of cell viability, cell migration, cell growth, and cell colony formation on all the studied cell lines. The expression of p-AKT, c-myc, p-ERK, ERα was inhibited, and γ-H2AX expression was induced. CONCLUSION: Combined inhibition of PARP and IL-6 may be an efficacious treatment for ovarian cancer, independently of BRCA mutation status.en_US
dc.description.urihttps://doi.org/10.21873/anticanres.15003en_US
dc.language.isoenen_US
dc.publisherInternational Institute of Anticancer Researchen_US
dc.relation.ispartofAnticancer Researchen_US
dc.rightsCopyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.en_US
dc.subjectBRCAen_US
dc.subjectIL-6 inhibitoren_US
dc.subjectPARPen_US
dc.subjectbazedoxifeneen_US
dc.subjectovarian canceren_US
dc.subjecttalazopariben_US
dc.titleSynergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.en_US
dc.typeArticleen_US
dc.identifier.doi10.21873/anticanres.15003
dc.identifier.pmid33952453
dc.source.volume41
dc.source.issue5
dc.source.beginpage2277
dc.source.endpage2286
dc.source.countryGreece


This item appears in the following Collection(s)

Show simple item record